Bluebird Bio Archives

News and Trends 22 Sep 2015

UniQure’s cure for rare Lysosomal disease ready for phase III trial

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur. UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year […]

September 22, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 18 Jun 2015

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston’s leading position in the gene therapy field. Gene Therapy is the next big thing in Biotech and is now moving from a theoretical dream to reality. Boston is clearly the hotspot for […]

June 18, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 10 Mar 2015

Live from Bio-Europe 2015: The product development challenges in the gene therapy field

Gene Therapy is really the hot topic right now in the field of Biotech especially with technologies such as CRISPR and CAR-T therapies. The value of such companies are skyrocketing and many see the field as the next potential blockbuster therapies. Gene therapy has clearly a huge potential but also lot of challenges, let’s go through […]

March 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 5 Dec 2014

Forbion Capital Partners: a Leading European Biotech VC is rising!

Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of its portfolio, to BTG plc, the UK-based specialist healthcare company for an initial cash consideration of €186M and up to €199M in performance-related future milestone payments. PneumRx is a growing interventional pulmonology business which owns, manufactures and distributes the RePneu Coil […]

December 5, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 1 Dec 2014

The First Gene Therapy Drug Will Be Sold at Record €1,1M Price

What could you buy with €1,1M euros? A house? Or a single prescription for a new drug… The first gene therapy drug “Glybera” is set to go on sale in Germany with a €1.1 million price tag, a new record for a medicine to treat a rare disease. And this drug from UniQure is not the only one […]

December 1, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 17 Oct 2014

Should European Biotech CEOs wear more sneakers?

Today is Friday or Casual Day. Did you leave the suit and the tie at home to wear jeans and sneakers? Should you have done so? More and more people do so on Friday but also the rest of the week. The American Tech industry and the Silicone Valley started the movement. Steve Jobs is probably the most […]

October 17, 2014 - 3 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us